The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …

Diabetic nephropathy has been traditionally diagnosed based on persistently high
albuminuria and a subsequent decline in glomerular filtration rate (GFR), which is widely …

The increasing epidemic of obesity worldwide is linked to serious health effects, including
increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic …

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …

Globally, diabetes is the leading cause of chronic kidney disease and end-stage renal
disease, which are major risk factors for cardiovascular disease and death. Despite this …

Diabetes adversely affects multiple organs, including the kidney, eye and nerve, leading to
diabetic kidney disease, diabetic retinopathy and diabetic neuropathy, respectively. In both …

Background & Aims Elafibranor is an agonist of the peroxisome proliferator− activated
receptor-α and peroxisome proliferator− activated receptor-δ. Elafibranor improves insulin …

Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic
complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease …

The prevalence of obesity-related glomerulopathy is increasing in parallel with the
worldwide obesity epidemic. Glomerular hypertrophy and adaptive focal segmental …

Diabetes mellitus (DM) is associated with several microvascular and macrovascular
complications, such as retinopathy, nephropathy, neuropathy, and cardiovascular diseases …